Our office will be closed on Monday, January 19, 2026, in observance of Martin Luther King Jr. Day.
We will resume normal operating hours on Tuesday, January 20, 2026.

Rivia Mind - Mental Healthcare You Can Trust
Click to Call
Refer a Patient

OCD Care in Real Life — Where Medication Fits and Where It Doesn’t

OCD Care in Real Life — Where Medication Fits and Where It Doesn’t

This article is written with mental health and healthcare providers in mind. If you’re not a provider, you’re still welcome to read along; just know the content is tailored to a clinical perspective.

Obsessive-Compulsive Disorder (OCD) is rarely straightforward. Behind the visible rituals and quiet distress is a web of intrusive thoughts, overactive brain circuits, and deeply ingrained behavioral loops. For providers, guiding someone through this territory is part detective work, part long game, figuring out what combination of tools can loosen the disorder’s grip enough for real progress to happen.

Exposure and Response Prevention (ERP) therapy — a type of cognitive behavioral therapy that gradually exposes patients to feared situations while helping them resist performing compulsions — remains the gold standard.1 But getting someone to fully engage in ERP can be another story. For many, symptoms need to come down a notch before they can start the work. That’s where medication can play a role — not as a cure-all, but as an important bridge to the rest of treatment.

The Neurochemical Links We Can’t Ignore

While OCD is defined by its behavioral patterns, its persistence often reflects deeper neurochemical imbalances. Research has identified shifts in three key systems:

  • Glutamate – the brain’s main excitatory neurotransmitter, responsible for speeding up communication between neurons. In some people with OCD, glutamate activity appears elevated in certain brain regions, potentially keeping threat detection and error-checking circuits stuck in overdrive.2
  • Gamma-aminobutyric acid (GABA) – the primary inhibitory neurotransmitter, acting as a counterbalance to glutamate. Lower GABA activity, or an unfavorable glutamate-to-GABA ratio, can make it harder to “quiet” intrusive thought loops.3
  • Serotonin – a regulator of mood and anxiety. Reduced serotonergic activity is strongly linked to OCD symptoms, and boosting serotonin through medication has been shown to reduce both intrusive thoughts and compulsive urges.4,5

 

For clinicians, these aren’t just interesting neurobiology facts — they map directly to treatment strategies. Medications that boost serotonin, particularly selective serotonin reuptake inhibitors (SSRIs), have become the backbone of first-line care. 

Older agents like clomipramine (tricyclic antidepressant with strong serotonergic activity) remain highly effective in some cases, especially for patients who don’t respond to SSRIs. Meanwhile, newer research into glutamate modulation is opening the door to potential future options for those with treatment-resistant OCD.

First-Line Isn’t Always Fast

SSRIs are the first-line choice in both APA and NICE treatment guidelines for OCD. But treating OCD with them is different from treating depression or generalized anxiety.

For one, doses are often higher. An SSRI dose that works for depression may barely touch intrusive thoughts in OCD. Sertraline, for example, might be titrated up to 200 mg per day or higher, assuming tolerability.

Second, the timeline is longer. A proper trial means maintaining the therapeutic dose for 10 to 12 weeks before deciding it’s ineffective.6 Stopping too soon is one of the most common reasons patients fail multiple medication attempts. In team-based care, it’s worth reinforcing these points so everyone understands why early changes aren’t always the right move.

When to Reach for Clomipramine

While meta-analyses suggest clomipramine can be slightly more effective than SSRIs, head-to-head trials don’t always find a clear superiority. And despite successful symptom reduction, clomipramine is reserved as a powerful second-line option due to its side effect profile.7,8

The trade-offs are significant: anticholinergic effects, weight gain, sexual side effects, and potential cardiac risks mean it’s best reserved for patients who haven’t responded to at least two adequate SSRI trials. When you do choose clomipramine, monitoring is essential — ECGs, careful review of other medications, and patient education about what to expect.

Augmentation: Adding with Intention

When an SSRI (or clomipramine) yields only a partial response, augmentation can be worth considering. The most consistent evidence supports low-dose atypical antipsychotics — especially risperidone or aripiprazole — as add-ons for SRI-resistant OCD. Meta-analyses and guideline reviews suggest roughly one-third of treatment-resistant patients respond to this strategy, with stronger signals when tics or poor insight are present; use the lowest effective dose and monitor metabolic risk and EPS closely.9

Not all antipsychotics are equal here. Evidence syntheses and NICE updates point to limited or no add-on benefit for quetiapine and olanzapine compared with placebo, reinforcing the focus on risperidone and aripiprazole as first-choice augmenters — and the importance of early reassessment if there’s no clear signal of benefit.10

For patients who remain stuck after optimized SRI trials (and, when appropriate, a careful antipsychotic add-on), glutamate-modulating agents are an option to consider with measured expectations. Memantine shows encouraging effects in small RCTs and meta-analyses of augmentation in moderate-to-severe OCD, but heterogeneity and scale limit firm conclusions; treat it as an adjunct for refractory cases, not a standard second step. Riluzole results are mixed, with a negative pediatric RCT and insufficient controlled adult data to recommend routine use.11

Practical guardrails: confirm you’ve given an adequate SRI trial at a therapeutic/high dose for ~12 weeks, add antipsychotics cautiously, and stop the augmentation if there’s no meaningful signal after a reasonable interval. Keep ERP active throughout so any pharmacologic gains translate into durable behavioral change.9,12

Medications Commonly Used for OCD and How They Work

As a recap — most pharmacologic treatment for OCD centers on serotonergic agents — either selective serotonin reuptake inhibitors (SSRIs) or, less often, serotonin-norepinephrine reuptake inhibitors (SNRIs). 

Commonly prescribed SSRIs for OCD include:

  • Fluvoxamine (Luvox)
  • Fluoxetine (Prozac)
  • Sertraline (Zoloft)
  • Paroxetine (Paxil)
  • Citalopram (Celexa)
  • Escitalopram (Lexapro)

Other serotonergic medications sometimes used:

  • Clomipramine (Anafranil) — a tricyclic antidepressant, generally reserved for second-line use.
  • Venlafaxine (Effexor) — an SNRI with some evidence for benefit in OCD, particularly when SSRIs are not tolerated.

Beyond their primary effects on serotonin, many of these agents can also help address common comorbidities, potentially streamlining the treatment plan. Depression is the most frequent (affecting an estimated 14–43% of individuals with OCD), while anxiety disorders are also typical.13

How Effective Is Medication for OCD?

Clinical evidence indicates that approximately 40–60% of patients with OCD experience a meaningful reduction in symptoms — often around 40–50% in severity — after 10 to 12 weeks on an adequate dose of a serotonin reuptake inhibitor. It’s important to note that full remission is uncommon, and most patients continue to experience some residual symptoms.14

An important factor to call out: Various studies suggest that teenagers may have an increased risk of suicidal thoughts and behaviors when taking SRIs. These patients should see their doctor or therapist more regularly at the beginning of treatment so that any risk of self-harm can be identified early on.15

Overall, it’s important to keep expectations grounded by emphasizing where the real advantage lies — in regaining enough control to participate fully in other therapeutic treatments.

Where Medication Doesn’t Fit

It’s tempting to reach for the prescription pad when progress slows, but not every plateau is pharmacologic. Sometimes, ERP is being done too cautiously to make a difference. Other times, avoidance behaviors outside of therapy are undermining progress. Life stressors — a chaotic home environment, ongoing trauma, major loss — can also blunt the impact of medication.

In these cases, adding or switching drugs may add unnecessary variables without addressing the underlying barrier. A candid assessment of what’s actually holding the patient back is essential before changing the medication plan.

Integrating Medication and ERP

In practice, ERP and medication work best together. Medication can lower the baseline anxiety enough to let patients fully engage in exposure work, while ERP provides the long-term coping skills that medication alone can’t.

Sequencing can matter. Some patients benefit from starting medication first, giving them a foothold before ERP begins. Others are motivated to dive into ERP right away and use medication as backup if progress stalls. Flexibility and close coordination between prescribers and therapists are key.

When ERP Isn’t the Whole Answer

ERP is still the backbone of OCD care, but it isn’t always the full story. Some patients aren’t ready to engage in exposure, others can’t sustain the intensity it requires, and certain comorbidities can muddy the waters. In these cases, broadening the therapeutic lens can keep treatment moving forward.

Cognitive therapy elements can help dismantle the distorted beliefs that keep compulsions in place. ACT can improve tolerance of distress when ERP feels overwhelming. Approaches like I-CBT or metacognitive therapy may offer traction for patients stuck in “thought about the thought” loops. Even supportive work has its place if it helps maintain adherence to ERP and medication.

For prescribers, knowing the therapy landscape matters — not to replace ERP, but to recognize when progress is stalling for reasons that medication adjustments alone won’t fix.

Thinking Long-Term

OCD is chronic for many patients, and relapse is common if treatment is withdrawn too quickly. Some research suggests continuing medication for at least one to two years after remission, with gradual tapering to minimize withdrawal effects and monitor for return of symptoms.16

Tapering while a patient is actively engaged in ERP can provide an extra layer of protection, as the skills learned in therapy can help manage any resurgence of intrusive thoughts or urges.

The Bottom Line

Medication is rarely the lead actor in the OCD story — but it can be the steady supporting role that lets the main treatment take center stage. Knowing when it fits and when it doesn’t keeps care grounded and avoids cycles of endless medication changes with no real gains.

For providers, that means using pharmacotherapy with intention, watching closely for where it’s helping and where it’s not, and keeping the broader treatment plan in focus. For patients, it means understanding that while medication can ease the path, lasting change comes from walking it — one exposure, resisted compulsion, and sustained choice at a time.

If you’re a provider with a patient who might benefit from a psychiatric consult or collaborative medication management, we’re here to make that handoff seamless. Call to speak to our Referral Intake Specialist at (929) 295-4879 or email referrals@riviamind.com to talk through options today.

References:

  1. International OCD Foundation.  OCD Treatment Guide: Best Evidence-Based Therapies, Medications, and New Advances, 2025.
  2. University College London. Research: People with obsessive-compulsive disorder have an imbalance of brain chemicals, 2023. 
  3. Cambridge University. Chemical imbalance in the forebrain underpins compulsive behaviour and OCD, 2023.
  4. Stanford Medicine. Obsessive Compulsive and Related Disorders. Pharmacological Treatments, 2025.
  5. CalmClinic. The Links Between OCD and Serotonin Deficiency, 2020.
  6. American Psychiatric Association. Practice Guideline For The Treatment of Patients With Obsessive-Compulsive Disorder, 2007.
  7. Piccinelli, M., Pini, S., Bellantuono, C., & Wilkinson, G. (1995). Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review. The British journal of psychiatry: the journal of mental science, 166(4), 424–443. https://doi.org/10.1192/bjp.166.4.424
  8. Naomi A. Fineberg, Angus Brown, Samar Reghunandanan, Ilenia Pampaloni, Evidence-based pharmacotherapy of obsessive-compulsive disorder, International Journal of Neuropsychopharmacology, Volume 15, Issue 8, September 2012, Pages 1173–1191, https://doi.org/10.1017/S1461145711001829
  9. Kayser R. R. (2020). Pharmacotherapy for Treatment-Resistant Obsessive-Compulsive Disorder. The Journal of clinical psychiatry, 81(5), 19ac13182. https://doi.org/10.4088/JCP.19ac13182
  10. Veale, D., Miles, S., Smallcombe, N., Ghezai, H., Goldacre, B., & Hodsoll, J. (2014). Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis. BMC psychiatry, 14, 317. https://doi.org/10.1186/s12888-014-0317-5
  11. Modarresi, A., Chaibakhsh, S., Koulaeinejad, N., & Rafieian Koupaei, S. (2019). A systematic review and meta-analysis: Memantine augmentation in moderate to severe obsessive-compulsive disorder. Psychiatry Research, 282, 112602. https://doi.org/10.1016/j.psychres.2019.112602
  12. Janardhan Reddy, Y. C., Sundar, A. S., Narayanaswamy, J. C., & Math, S. B. (2017). Clinical practice guidelines for Obsessive-Compulsive Disorder. Indian journal of psychiatry, 59(Suppl 1), S74–S90. https://doi.org/10.4103/0019-5545.196976 
  13. Sharma, E., Sharma, L. P., Balachander, S., Lin, B., Manohar, H., Khanna, P., Lu, C., Garg, K., Thomas, T. L., Au, A. C. L., Selles, R. R., Højgaard, D. R. M. A., Skarphedinsson, G., & Stewart, S. E. (2021). Comorbidities in Obsessive-Compulsive Disorder Across the Lifespan: A Systematic Review and Meta-Analysis. Frontiers in psychiatry, 12, 703701. https://doi.org/10.3389/fpsyt.2021.703701 
  14. International OCD Foundation. Understanding Medication for OCD, 2025.
  15. InformedHealth.org. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2006-. Obsessive-compulsive disorder (OCD): Learn More – Treatments for obsessive-compulsive disorder. [Updated 2021 Jul 27]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK279561/ 
  16. Janardhan Reddy, Y. C., Sundar, A. S., Narayanaswamy, J. C., & Math, S. B. (2017). Clinical practice guidelines for Obsessive-Compulsive Disorder. Indian journal of psychiatry, 59(Suppl 1), S74–S90. https://doi.org/10.4103/0019-5545.196976 
Categories
Recent Posts
Tags